Clinical trial
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
NCT06751524
Study timeline
Registry last updated2026-05-15
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Colorectal Cancer (CRC)unresolved
Non-Small Cell Lung Cancer (NSCLC)unresolved
Hepatocellular Carcinoma (HCC)unresolved
Melanomaverified · MONDO: melanoma
Sarcomaverified · MONDO: sarcoma
Ovarian Cancerverified · MONDO: ovarian cancer
Prostate Cancerverified · MONDO: prostate cancer
Interventions
BotensilimabDRUG
BalstililmabDRUG
Sponsors & collaborators
Agenus Inc.lead sponsor
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06751524 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.